Targeting Enzymes in the Brain
- 1st Edition, Volume 102 - February 5, 2025
- Imprint: Academic Press
- Editor: Takashi Tsukamoto
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 3 4 2 9 2 - 9
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 3 4 2 9 3 - 6
Targeting Enzymes in the Brain series, highlights new advances in the field, with this new volume presenting interesting chapters. Each chapter is written by an intern… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteTargeting Enzymes in the Brain series, highlights new advances in the field, with this new volume presenting interesting chapters. Each chapter is written by an international board of authors.
- Provides the latest information on brain enzyme researches
- Offers outstanding and original reviews on a range of brain enzyme research topics
- Serves as an indispensable reference for researchers and students alike
Provides invaluable information on the fast-moving field of brain enzyme researches that includes outstanding original reviews on a variety of topics
- Title of Book
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- Reference
- Chapter One: Targeting PAAN/MIF nuclease activity in parthanatos-associated brain diseases
- Abstract
- Abbreviations
- 1 Introduction
- 2 Conclusion
- Acknowledgments
- References
- Chapter Two: Inhibition of brain glutamate carboxypeptidase II (GCPII) to enhance cognitive function
- Abstract
- Abbreviations
- 1 Introduction
- 2 The role of GCPII inhibition and NAAG in cognition and disease
- 3 Preclinical and clinical research examining the role of GCPII and NAAG in cognition
- 4 Efforts to develop GCPII inhibitors
- 5 Future directions
- References
- Chapter Three: Neutral sphingomyelinase 2: A promising drug target for CNS disease
- Abstract
- Abbreviations
- 1 Introduction
- 2 The role and therapeutic potential of nSMase2 in CNS diseases
- 3 Therapeutic potential of nSMase2 inhibitors in non-CNS diseases
- 4 Conclusion
- Acknowledgments
- References
- Chapter Four: Biological and therapeutic significance of targeting NLRP3 inflammasome in the brain and the current efforts to develop brain-penetrant inhibitors
- Abstract
- Abbreviations
- 1 Introduction
- 2 Structure, activation, and functions of the NLRP3 inflammasome
- 3 Association of the NLRP3 Inflammasome with Diseases
- 4 Therapeutic Significance of NLRP3
- 5 Challenges in the development of NLRP3 inhibitors
- 6 Conclusion
- Acknowledgments
- References
- Chapter Five: Phosphodiesterase 4 (PDE4) and neurological disorders: A promising frontier in neuropharmacology
- Abstract
- Abbreviations
- 1 Introduction
- 2 The biology of PDE: structure, function, and regulation
- 3 PDE4 distribution in the brain: a map of function
- 4 Overview of existing PDE4 inhibitors
- 5 PDE4 in neurological disorders: therapeutic frontiers
- 6 Challenges and future directions of PDE4 and neurological disorders
- 7 Conclusion
- References
- Chapter Six: Modulatory and protective effects of prolyl hydroxylase domain inhibitors in the central nervous system
- Abstract
- Abbreviations
- 1 Introduction
- 2 PHDIs as a therapeutic option in stroke
- 3 Actions of PHDIs in neurodegenerative disorders
- 4 PHDIs in traumatic CNS disorders
- 5 Actions of PHDI on synaptic transmission and plasticity
- 6 Clinical relevance of PHDIs in neurological disorders
- 7 Conclusion
- References
- Chapter Seven: Soluble epoxide hydrolase: Mechanisms and therapeutic potential in psychiatric and neurological disorders
- Abstract
- Abbreviations
- 1 Introduction
- 2 Role of sEH in psychiatric and neurological disorders
- 3 Clinical studies of sEH inhibitors
- 4 Conclusion
- Acknowledgments
- References
- Chapter Eight: Drug discovery strategy for TAK-418, a specific inhibitor of LSD1 enzyme activity, as a novel therapy for autism
- Abstract
- Abbreviations
- 1 Introduction
- 2 Epigenetic modulation as the potential therapeutic target for ASD
- 3 Discovery of LSD1 “enzyme activity-specific” inhibitors
- 4 Positron emission tomography (PET) tracer discovery
- 5 Conclusion
- Conflict of interest statement
- References
- Chapter Nine: Evolution of D-amino acid oxidase inhibitors: From concept to clinic
- Abstract
- Abbreviations
- 1 Introduction
- 2 Evolution of DAAO inhibitors
- 3 Preclinical in vivo pharmacology of representative DAAO inhibitors
- 4 Clinical pharmacology
- 5 Conclusion
- Acknowledgments
- References
- Edition: 1
- Volume: 102
- Published: February 5, 2025
- No. of pages (Hardback): 360
- No. of pages (eBook): 312
- Imprint: Academic Press
- Language: English
- Hardback ISBN: 9780443342929
- eBook ISBN: 9780443342936
Read Targeting Enzymes in the Brain on ScienceDirect